Dose-Escalated Focal Salvage High-Dose-Rate Brachytherapy and Genomic Classifier Risk Stratification in Radiorecurrent Prostate Cancer: The F-SHARP Phase I/II Clinical Trial

医学 近距离放射治疗 泌尿生殖系统 前列腺 前列腺癌 临床试验 肿瘤科 放射治疗 内科学 前瞻性队列研究 剂量分馏 总体生存率 生活质量(医疗保健) 挽救疗法 前列腺切除术 外照射放疗 危险分层 放射科 直肠炎 临床研究阶段 毒性 队列 生存分析 疾病 前列腺特异性抗原 临床终点
作者
Abhishek Ashok Solanki,William Adams,James A. Proudfoot,Kristin G. Baldea,Guliz Akdas Barkan,Alec M. Block,Neil Bipinchandra Desai,Ahmer V Farooq,Michael R. Folkert,Aurélie Garant,Alex Gorbonos,Gopal Nand Gupta,Hyejoo Kang,Eileen M. Kelly,Steven Kregel,Stanley L. Liauw,C. Luminais,Michael L. Mysz,Marcus Lee Quek,Timothy Norman Showalter
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (33): 3213-3226
标识
DOI:10.1200/jco-25-02730
摘要

Purpose Prospective data on the management of intraprostatic radiorecurrence (IPR) after definitive radiotherapy (RT) and use of genomic classifiers (GC) in this setting are limited. We hypothesized that dose-escalated focal salvage high-dose-rate brachytherapy (DE-fsHDR) would be safe and effective, and that GC would risk stratify patients who may benefit from treatment intensification. Methods F-SHARP is a multi-institutional phase I/II trial of DE-fsHDR for IPR after any form of RT for localized prostate cancer. Patients received up to 30 Gy in 1-2 fractions. The primary objective was to determine the acute RT-related grade ≥3 CTCAE v4.03 genitourinary and GI toxicity rates. Secondary end points included all-grade toxicity, quality of life (QoL; EPIC-26 and International Prostate Symptom Score), disease control, and survival. GC analysis used a clinical-grade transcriptome assay (Veracyte, San Diego, CA). Time-to-event outcomes included biochemical progression-free survival (bPFS), radiographic progression-free survival (rPFS), local recurrence-free survival (LRFS), and metastasis-free survival (MFS). Results Twenty-four participants received one fraction and 38 received two fractions (N = 62). The median follow-up was 39.4 months. No acute grade 3 toxicities occurred. Two patients (3.2%) had late grade 3 toxicity. QoL changes did not meet criteria for a minimal clinically important difference. Three-year survival rates were 62.7% (bPFS), 67.5% (rPFS), 73.0% (LRFS), and 85.9% (MFS); there were no differences between fractionation groups (all P > .05). Among 31 patients with GC results, higher scores were associated with worse bPFS, rPFS, LRFS, and MFS. All patients with GC score >0.85 (n = 4) experienced biochemical, local, and metastatic recurrence. Conclusion DE-fsHDR is a safe and effective salvage treatment for IPR. GC score is a promising prognostic tool in patients undergoing salvage local therapy for IPR and warrants further study to guide treatment intensification.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
tangerine发布了新的文献求助10
刚刚
科研通AI2S的应助被随便叫什么采纳,获得10
1秒前
1秒前
烟花的应助被开朗的小蘑菇采纳,获得10
2秒前
3秒前
4秒前
wanci的应助被披日悬光采纳,获得10
5秒前
大黄的应助被yqhuang采纳,获得10
5秒前
李雅欣发布了新的文献求助10
6秒前
秋风的应助被Dicy采纳,获得10
6秒前
慧眼的切糕k完成签到 ,获得积分10
6秒前
Zack发布了新的文献求助10
7秒前
知道知道什么都知道完成签到,获得积分10
7秒前
Lsmile完成签到 ,获得积分10
8秒前
8秒前
8秒前
8秒前
9秒前
east发布了新的文献求助10
9秒前
10秒前
Lucas的应助被WYL采纳,获得10
10秒前
莹莹发布了新的文献求助10
10秒前
888发布了新的文献求助50
10秒前
虎虎完成签到,获得积分10
11秒前
脑洞疼的应助被青菜采纳,获得30
11秒前
11秒前
慧眼的切糕k关注了科研通微信公众号
12秒前
cdercder的应助被zzk采纳,获得10
12秒前
昭昭完成签到 ,获得积分10
12秒前
13秒前
pursuer发布了新的文献求助10
13秒前
13秒前
留蓝发布了新的文献求助10
14秒前
Helen028完成签到,获得积分10
14秒前
亦天凛发布了新的文献求助10
14秒前
16秒前
17秒前
lethe发布了新的文献求助10
18秒前
科研通AI6.4的应助被萧小五采纳,获得10
18秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193361
求助须知:如何正确求助?哪些是违规求助? 9579602
关于积分的说明 21866201
捐赠科研通 7792983
什么是DOI,文献DOI怎么找? 3437263
关于科研通互助平台的介绍 2560718
邀请新用户注册赠送积分活动 2484082